ArticleFrontiers in nephrology2026
Predictors of renal and patient survival in lupus nephritis: a 28-year single-center cohort study.
Article in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Despite advances in the understanding and treatment of lupus nephritis (LN), long-term renal and patient outcomes remain suboptimal. Identifying reliable predictors of prognosis and early treatment response is essential for improving risk stratification and guiding management. Methods: We conducted a retrospective cohort study of patients with biopsy-proven LN. Long-term renal and patient survival, renal response at 6 and 12 months, and predictors of a composite outcome (doubling of serum creatinine, end-stage kidney disease [ESKD], or death) were evaluated. Results: A total of 147 patients were included, with a median follow-up of 39.5 months. 10.3% of patients had a doubling of serum creatinine, 11.0% progressed to ESKD, and 6.8% died. Proteinuria <0.7 g/day was achieved by 49.1% and 54.4% of patients at 6 and 12 months, respectively. In multivariate analysis, baseline predictors of the composite outcome included age >50 years, proteinuria ≥3 g/day, and hemoglobin <10 g/dL, while an activity index ≥9 and low baseline C4 levels showed a protective trend. Achieving proteinuria <0.7 g/day at 12 months emerged as the strongest protective factor. A prognostic score demonstrated good discrimination (area under the curve [AUC] 0.82), which improved further with the addition of proteinuria at 12 months (AUC 0.86). Conclusions: In this biopsy-proven LN cohort, early renal response, particularly proteinuria <0.7 g/day at 12 months, was the strongest predictor of long-term renal and patient survival. These findings support a dynamic, response-based approach to prognostication in LN and provide the basis for a clinically applicable prognostic score that requires external validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.